Benoit Dubé, Tami Benton, Dean G. Cruess, Dwight L. Evans. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30(4):237-246.
Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depres- sion: a systematic review of interventions. Psychology Health and Medicine 2011; 16:493-527.
Bakım B, Özçelik B, Karamustafalıoğlu O. Psychiatric disorders among patients with HIV infection. Düşünen Adam 2005; 18(3):149-156.
Bing EG, Burnam A, Longshore D, Fleishman JA, Sher-bourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-728.
Zhang L, Yang D, Zhao HX, Han N, Xiao J, Chen YF, et al. Assessment on depressive status and the therapeutic effects of highly active antiretroviral therapy among anti-HIV-1(+) popula- tion. Zhonghua Liu Xing Bing Xue Za Zhi 2013; 34(5):461-463.
Im SG, Ng TM, Kung N, Volfova M, Husa P, Lee SS, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166:49-56.
Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46(6):1734-1740.
O'Mahony SM, Myint AM, Steinbusch H, Leonard BE. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation 2005; 12:293-298.
Duarte-Rojo A, Heathcote EJ. Efficacy and safety of teno-fovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010; 3:107-119.